MedTrace Logo

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

NCT04708821 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-04-13

No results posted yet for this study

Summary

This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to compare patient-reported and clinical outcomes with DEXTENZA versus topical steroid or antihistamine treatment in patients with allergic conjunctivitis

Conditions

  • Bilateral Conjunctivitis (Disorder)

Interventions

DRUG

Dexamethasone ophthalmic insert 0.4Mg

Dextenza 0.4Mg Ophthalmic Insert

DRUG

0.2% loteprednol etabonate ophthalmic suspension

0.2% loteprednol etabonate ophthalmic suspension

DRUG

olopatadine hydrochloride ophthalmic solution 0.7%

olopatadine hydrochloride ophthalmic solution 0.7%

Sponsors & Collaborators

  • Ocular Therapeutix, Inc.

    collaborator INDUSTRY

  • Clinical Research Center of Florida

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2021-09-02
Completion
2021-09-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04708821 on ClinicalTrials.gov